SGLT2 inhibitor to prevent liver problems in hepatitis B and diabetes
Treatments studied
Part of Digestive system, Infections clinical trials.
This study tests if adding a diabetes medicine called an SGLT2 inhibitor to your current treatment can help prevent liver complications in people with chronic hepatitis B and type 2 diabetes or prediabetes. If you have early liver scarring and stable diabetes treatment, this could offer extra protection for your liver.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic hepatitis B and have been on a standard antiviral medicine (entecavir, tenofovir, or tenofovir alafenamide) for at least a year.
- You have type 2 diabetes or prediabetes, and your blood sugar is not severely high (HbA1c no more than 9%).
- You are taking one or two diabetes medicines that have been stable (no changes) for the last 3 months.
- You have early liver scarring (advanced fibrosis or early cirrhosis) without complications, or signs of increased pressure in the liver area.
- You cannot have other serious liver diseases (like hepatitis C), liver cancer, organ transplant, or severe kidney disease.
- You must be 18 or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if an SGLT2 inhibitor can help protect kidney function in people who have lupus nephritis (kidney inflammation caused by lupus) and chronic kidney disease (CKD). The goal is to see if this medicine can slow down further kidney damage.
This study tests whether a class of diabetes drugs called SGLT2 inhibitors can help reduce fat in the liver for people with type 2 diabetes and chronic kidney disease. If you have both conditions, this treatment might improve your liver health.
This study tests how a type of diabetes medicine called SGLT2 inhibitors affects how the liver makes sugar. It may help researchers better understand how to manage blood sugar in people with type 2 diabetes.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This study tests a medication called dapagliflozin (a drug used for diabetes) to see if it can help people with advanced liver disease and fluid build-up in the belly that does not go away with standard care. It may offer a new way to manage this difficult condition.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.